Vineetha K K
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vineetha K K has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Rajeshwari Gurumoorthy Bhat
Department of Obstetrics and Gynaecology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India
3 shared publications - Archana Parampalli Raghavendra
Division of Physiology, Department of Basic Medical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India
2 shared publications - Bhamini Krishna Rao
Department of Physiotherapy, Manipal College of Health Professions, Manipal Academy of Higher Education, Manipal, India
2 shared publications Archana P R
Department of Basic Medical Sciences Manipal Academy of Higher Education Manipal Karnataka India
1 shared publicationBabi Dutta
Department of Basic Medical Sciences Manipal Academy of Higher Education Manipal Karnataka India
1 shared publicationBhamini Krishna Rao
Department of Physiotherapy, Manipal College of Health Professions Manipal Academy of Higher Education Manipal Karnataka India
1 shared publication
Latest Publications
- Open Access
- 28 February 2025
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 32
Development and validation of uterine fibroid quality of life and health-related lifestyle (UF-QLHRL) questionnaire in an Indian population
- 28 February 2025
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 32
Open AccessDevelopment and validation of uterine fibroid quality of life and health-related lifestyle (UF-QLHRL) questionnaire in an Indian population
- 12 October 2024
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 38 (24) , e9923
GC–MS quantification of fecal short‐chain fatty acids and spectrophotometric detection of indole: Do rectal swabs produce comparable results as stool samples? ‐ A pilot study
Rationale: The exploration of the gut microbiome and related metabolites holds an exciting future in health science. The challenges associated with fecal sample testing are proper sample collection, sterile transportation, optimal transport conditions, and processing as all these factors could potentially change the microbiome composition, further exacerbated by the patient's customary discomfort regarding feces samples. The study aimed to compare the usage of rectal swabs and stool samples for short‐chain fatty acid estimation using gas chromatography–mass spectrometry (GC–MS) and indole estimation using spectrophotometry. Method: From May 2022 to June 2022, three women were recruited from the Department of Obstetrics and Gynecology (OBG) in a secondary care hospital in coastal Karnataka. During their clinical visit, a rectal swab was collected, and the stool sample was transported to the hospital from the patient's home in sterile containers provided. After the extraction, short‐chain fatty acids (acetate, propionate, and butyrate) were quantified using GC–MS. The fecal indole concentration was determined using a hydroxylamine‐based assay. Results: The GC–MS analysis failed to detect the concentrations of short‐chain fatty acids in rectal swab samples. Indole concentrations in stool and swab samples were significantly different. Conclusion: The study's findings do not support the use of rectal swabs to analyze gut metabolites.
- 12 October 2024
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 38 (24) , e9923
GC–MS quantification of fecal short‐chain fatty acids and spectrophotometric detection of indole: Do rectal swabs produce comparable results as stool samples? ‐ A pilot study
Rationale: The exploration of the gut microbiome and related metabolites holds an exciting future in health science. The challenges associated with fecal sample testing are proper sample collection, sterile transportation, optimal transport conditions, and processing as all these factors could potentially change the microbiome composition, further exacerbated by the patient's customary discomfort regarding feces samples. The study aimed to compare the usage of rectal swabs and stool samples for short‐chain fatty acid estimation using gas chromatography–mass spectrometry (GC–MS) and indole estimation using spectrophotometry. Method: From May 2022 to June 2022, three women were recruited from the Department of Obstetrics and Gynecology (OBG) in a secondary care hospital in coastal Karnataka. During their clinical visit, a rectal swab was collected, and the stool sample was transported to the hospital from the patient's home in sterile containers provided. After the extraction, short‐chain fatty acids (acetate, propionate, and butyrate) were quantified using GC–MS. The fecal indole concentration was determined using a hydroxylamine‐based assay. Results: The GC–MS analysis failed to detect the concentrations of short‐chain fatty acids in rectal swab samples. Indole concentrations in stool and swab samples were significantly different. Conclusion: The study's findings do not support the use of rectal swabs to analyze gut metabolites.
- Open Access
- 7 July 2023
- Published by Springer Nature in Reproductive Sciences
- Vol. 30 (12) , 3443-3455
The Gut Microbiota: a Novel Player in the Pathogenesis of Uterine Fibroids
Uterine fibroid is a common gynecological disorder that affects women of reproductive age and has emerged as a major public health concern. The symptoms have a negative influence on both their physical health and quality of life. The cost of treatment has a significant impact on the disease’s burden. Even though its origin is uncertain, estrogen is thought to be a key player in fibroid pathophysiology. Many theories, including those based on genetic and environmental factors, explain what causes hyper-estrogenic condition in fibroid patients. One such possibility that is currently being explored is the hypothesis that an altered gut microbiome can contribute to the development of diseases characterized by estrogen dominance. Gut dysbiosis is often a “hot area” in the health sciences. According to a recent study, uterine fibroid patients have altered gut microbiome. A variety of risk factors influence both fibroid development and gut homeostasis. Diet, lifestyle, physical activity, and environmental contaminants have an impact on estrogen and the gut flora. A better understanding of uterine fibroids’ pathophysiology is required to develop effective preventative and treatment options. A few ways by which the gut microbiota contributes to UF include estrogen, impaired immune function, inflammation, and altered gut metabolites. Therefore, in the future, while treating fibroid patients, various strategies to deal with changes in the gut flora may be advantageous. For developing suggestions for clinical diagnosis and therapy, we reviewed the literature on the relationship between uterine fibroids and the gut microbiota.
- 7 July 2023
- Published by Springer Nature in Reproductive Sciences
- Vol. 30 (12) , 3443-3455
Open AccessThe Gut Microbiota: a Novel Player in the Pathogenesis of Uterine Fibroids
Uterine fibroid is a common gynecological disorder that affects women of reproductive age and has emerged as a major public health concern. The symptoms have a negative influence on both their physical health and quality of life. The cost of treatment has a significant impact on the disease’s burden. Even though its origin is uncertain, estrogen is thought to be a key player in fibroid pathophysiology. Many theories, including those based on genetic and environmental factors, explain what causes hyper-estrogenic condition in fibroid patients. One such possibility that is currently being explored is the hypothesis that an altered gut microbiome can contribute to the development of diseases characterized by estrogen dominance. Gut dysbiosis is often a “hot area” in the health sciences. According to a recent study, uterine fibroid patients have altered gut microbiome. A variety of risk factors influence both fibroid development and gut homeostasis. Diet, lifestyle, physical activity, and environmental contaminants have an impact on estrogen and the gut flora. A better understanding of uterine fibroids’ pathophysiology is required to develop effective preventative and treatment options. A few ways by which the gut microbiota contributes to UF include estrogen, impaired immune function, inflammation, and altered gut metabolites. Therefore, in the future, while treating fibroid patients, various strategies to deal with changes in the gut flora may be advantageous. For developing suggestions for clinical diagnosis and therapy, we reviewed the literature on the relationship between uterine fibroids and the gut microbiota.